4 active not recruiting, 4 completed, 2 terminated, 1 not yet recruiting. 8 Phase 1, 7 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Active not recruiting 2, Not yet recruiting 1, Recruiting 1 |
| Phase 2 | 7 | Active not recruiting 3, Completed 2, Terminated 2 |
| Not applicable | 1 | Active not recruiting 1 |
Follow Refractory Anaplastic Large Cell Lymphoma: new trials by email Literature Review of Refractory Anaplastic Large Cell Lymphoma trials Research Report on Refractory Anaplastic Large Cell Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma Azacitidine, Belinostat, Biospecimen Collection - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma | Phase 1 | Not yet recruiting | City of Hope Medical Center | 40 | 2027-01-03 | 2026-07-09 |
| Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas Parsaclisib, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Phase 1 | Completed | Walter Hanel | 5 | 2021-09-01 | 2025-01-17 |
| Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas Anti-CD30/CD16A Monoclonal Antibody AFM13, Cyclophosphamide, Fludarabine - Recurrent Anaplastic Large Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 45 | 2020-07-18 | 2026-09-30 |
| Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas Pembrolizumab, Pralatrexate - Anaplastic Large Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma With TFH Phenotype | Phase 1 / Phase 2 | Active not recruiting | City of Hope Medical Center | 13 | 2019-02-04 | 2026-05-26 |
| Study of Pembrolizumab (MK-3475) in Combination With Romidepsin Pembrolizumab, Romidepsin - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 39 | 2017-11-14 | 2026-09-30 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-08-13 |
| Nivolumab in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Laboratory Biomarker Analysis, Nivolumab - Blastic Plasmacytoid Dendritic Cell Neoplasm, Hepatosplenic T-Cell Lymphoma | Phase 2 | Terminated | Mayo Clinic | 12 | 2017-05-17 | 2020-04-21 |
| A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma Biopsy Procedure, Biospecimen Collection, Bone Marrow Biopsy - B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm | Phase 1 | Recruiting | Mayo Clinic | 99 | 2017-04-04 | 2026-06-10 |
| Phase 2 Study of AT13387 (Onalespib) in ALK+ ALCL, MCL, and BCL-6+ DLBCL Onalespib - Recurrent Anaplastic Large Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 25 | 2016-04-04 | 2022-09-13 |
| Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency Cholecalciferol, Laboratory Biomarker Analysis - Aggressive Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma | Not applicable | Active not recruiting | Mayo Clinic | 565 | 2013-03-06 | 2026-06-16 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma Carboplatin, Etoposide, Ifosfamide - Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma | Phase 1 | Completed | M.D. Anderson Cancer Center | 22 | 2012-10-29 | 2018-09-19 |
| Crizotinib in Treating Younger Patients With Relapsed or Refractory Solid Tumors or Anaplastic Large Cell Lymphoma Crizotinib, Laboratory Biomarker Analysis, Pharmacological Study - Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Malignant Solid Neoplasm | Phase 1 / Phase 2 | Completed | Children's Oncology Group | 122 | 2009-09-21 | 2020-06-09 |
Lymphoma, Large-Cell, Anaplastic (12) · Lymphoma, T-Cell (10) · Mycosis Fungoides (7) · Immunoblastic Lymphadenopathy (6) · Enteropathy-Associated T-Cell Lymphoma (5) · Lymphoma, T-Cell, Cutaneous (4) · Subcutaneous panniculitis-like T-cell lymphoma (3) · Lymphoma, B-Cell (2) · Lymphoma, Extranodal NK-T-Cell (2) · Lymphoma, Large B-Cell, Diffuse (2) · Adenocarcinoma, Papillary (1) · Blastic Plasmacytoid Dendritic Cell Neoplasm (1) · Carcinoma, Basal Cell (1) · Carcinoma, Basosquamous (1) · Carcinoma, Merkel Cell (1)
Hemic and Lymphatic Diseases (12) · Immune System Diseases (12) · Immunoproliferative Disorders (12) · Lymphatic Diseases (12) · Lymphoma (12) · Lymphoma, Non-Hodgkin (12) · Lymphoproliferative Disorders (12) · Neoplasms (12) · Neoplasms by Histologic Type (12) · Lymphadenopathy (6) · Lymphoma, T-Cell, Cutaneous (5) · Hematologic Diseases (3) · Leukemia (3) · Infections (2) · Leukemia, Lymphoid (2)
Depsipeptides (3) · Lactones (3) · Nivolumab (3) · Specimen Handling (3) · romidepsin (3) · 10-propargyl-10-deazaaminopterin (2) · Biopsy (2) · Cyclophosphamide (2) · Magnetic Resonance Spectroscopy (2) · pembrolizumab (2) · (2,4-dihydroxy-5-isopropylphenyl)-(5-(4-methylpiperazin-1-ylmethyl)-1,3-dihydroisoindol-2-yl)methanone (1) · AFM13 (1) · Azacitidine (1) · Carboplatin (1) · Cholecalciferol (1)
M.D. Anderson Cancer Center (3) · Mayo Clinic (3) · City of Hope Medical Center (2) · National Cancer Institute (NCI) (2) · Children's Oncology Group (1) · Walter Hanel (1)
United States (12) · Canada (1)
Alex F Herrera (1) · Caron A Jacobson (1) · Christina Poh (1) · Joselle Cook, M.B.B.S. (1) · Michelle Fanale (1) · Nora Bennani, M.D. (1) · Stephen Ansell (1) · Swaminathan P Iyer, MD (1) · Thomas E. Witzig, MD (1) · Walter Hanel, MD, PhD (1) · Yael P Mosse (1) · Yago L Nieto (1)
PMID 23598171, PMID 28032129, PMID 29622656, PMID 33568345, PMID 35175355, PMID 35750419, PMID 36898933, PMID 40186077, PMID 41920422
UM1CA186709 (2), P30CA015083 (1), P30CA016672 (1), P30CA033572 (1), P50CA097274 (1), P50CA186781 (1), R01CA262613 (1), UM1CA097452 (1), UM1CA186690 (1), UM1CA186716 (1)